['metastatic pancreatic adenocarcinoma']
['z-360', 'placebo']

        Inclusion Criteria:

          -  1. Subjects with histological or cytological evidence of metastatic Pancreatic
             Adenocarcinoma, Measurable disease or non-measurable disease by Response Evaluation
             Criteria in Solid Tumors (RECIST) version criteria

          -  2. Subjects with a life expectancy of at least 12 weeks,

          -  3. Subjects with an Eastern cooperative oncology group performance status (ECOG PS) of
             0, 1 or 2,

          -  4. Subjects with the following adequate organ functions:

               -  White blood cell count ≥3,000/μL (or absolute neutrophil count ≥1,500/μL) and ≤
                  12,000/μL ,

               -  Platelet count ≥100.0 × 10^9/L,

               -  Hemoglobin ≥9.0 g/dL,

               -  Serum creatinine ≤1.5 × the upper limit normal (ULN),

               -  Total bilirubin ≤2.0 × ULN,

               -  Serum aspartate transaminase levels ≤3.0 × ULN (≤5.0 × ULN in presence of liver
                  metastases), and

               -  Serum alanine aminotransferase levels ≤3.0 × ULN (≤5.0 × ULN in presence of liver
                  metastases).

        Exclusion Criteria:

          -  Subjects received the following previous therapies for Pancreatic Adenocarcinoma:

               -  Surgery within the 4 weeks prior to randomization,

               -  Radiation and chemoradiation within the 12 weeks prior to randomization,

               -  Radiation for pain relief within the 4 weeks prior to randomization,

               -  Gemcitabine used as a neoadjuvant or an adjuvant on surgery within the 24 weeks
                  prior to randomization,

               -  Chemotherapy except GEM used as an adjuvant on surgery within the 4 weeks prior
                  to randomization,

               -  Gemcitabine ≥600 mg/m^2 as sensitizer for chemoradiation,

               -  Gemcitabine <600 mg/m^2 as sensitizer for chemoradiation within the 12 weeks
                  prior to randomization,

               -  Gemcitabine used for systemic chemotherapy, or

               -  Systemic chemotherapies except GEM within the 4 weeks prior to randomization.
      